Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04783935
Status:
COMPLETED
Last Update Posted:
2024-04-23
First Post:
2021-03-03
Brief Title:
Extension to the MAGNIFY MS Trial on Mavenclad Magnify MS Extension
Sponsor:
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Organization:
Merck Healthcare KGaA Darmstadt Germany an affiliate of Merck KGaA Darmstadt Germany
Study Overview
Official Title:
A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad in Participants Who Have Completed Trial MS700568_0022 MAGNIFY MS Magnify MS Extension
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the long-term effectiveness of Mavenclad tablets in terms of disease activity and safety in participants with highly-active relapsing multiple sclerosis RMS previously participating in the MAGNIFY MS trial MS700568_0022 NCT03364036
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-003995-42 | EUDRACT_NUMBER | None | None |